申请人:JACKSON WILLIAM PAUL
公开号:WO2009146871A1
公开(公告)日:2009-12-10
The use of compounds of the formula (I) Ar1-L1-Ar2-L2-C(R3)(R4)N(OR1)C(=Y)-R2 (I) where Y is selected from O or S; R1 is H, a salt or readily hydrolysable substituent; R2 is selected from H or CH3, CH2F, CF2H or CF3; R3 and R4 are selected independently from H, C 1-4 alkyl or alkenyl, CF3, CH2F, CF2H and F, with the proviso that if either R3 or R4 is H, then the other is not H; L1 is a linker group; L2 is a linker group comprising an optionally substituted or unsubstituted unsaturated branched or straight chain alkyl group; Ar1 is an optionally substituted or unsubstituted aryl or heterocyclic group; and Ar2 is an optionally substituted or unsubstituted aryl or heterocyclic group, in the treatment of 5-lipoxygenase mediated cancer provide improved therapies due to the effective inhibition of 5- lipoxygenase and long duration of activity in vivo after oral administration.
使用式(I) Ar1-L1-Ar2-L2-C(R3)(R4)N(OR1)C(=Y)-R2(I)的化合物,在此式中Y选择自O或S;R1为H、盐或易水解的取代基;R2选择自H或CH3、CH2F、CF2H或CF3;R3和R4独立选择自H、C1-4烷基或烯基、CF3、CH2F、CF2H和F,但如果R3或R4之一为H,则另一个不是H;L1为连接基;L2为包含可选择取代或未取代的不饱和分支或直链烷基的连接基;Ar1为可选择取代或未取代的芳基或杂环基;Ar2为可选择取代或未取代的芳基或杂环基,在治疗5-脂氧合酶介导的癌症中,由于对5-脂氧合酶的有效抑制和口服给药后体内活性持续时间长,可提供改进的疗法。